NCT01009788 - ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2015

Conditions

Breast CancerMetastatic Breast CancerBRCA1 Gene Mutationbrca2 Gene Mutation

Interventions

DRUG

ABT-888

Capsules (30-40 mg) taken orally twice a day on days 1-7 of each 28 day cycle

DRUG

temozolomide

Capsules (150 mg/m\^2 initially, and 200 mg/m\^2 starting cycle 2 if tolerated) taken orally once a day on days 1 through 5 of a 28 day cycle

Trial Locations (3)

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston